GLADIUS PHARMACEUTICALS CORP has a total of 16 patent applications. It increased the IP activity by 66.0%. Its first patent ever was published in 2008. It filed its patents most often in United States, Japan and EPO (European Patent Office). Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and basic materials chemistry are CROPSOLUTION INC, ANTOXIS LTD and ASTAR BIOTECH LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | Japan | 3 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Canada | 1 | |
#6 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Basic materials chemistry | |
#4 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Preservation of human bodies | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Yu Sophia | 15 |
#2 | Sutton Larry D | 7 |
#3 | Sutton Larry | 6 |
#4 | Larry Sutton | 2 |
#5 | Hassanpour Avid | 1 |
#6 | Larry D Sutton | 1 |
#7 | Vidal Marc | 1 |
#8 | Zamboni Robert | 1 |
#9 | Bureau Patrick | 1 |
#10 | Zhou Nancy | 1 |
Publication | Filing date | Title |
---|---|---|
WO2019070973A1 | Cephem compounds with latent reactive groups | |
US2016031906A1 | Derivatized 3-styryl-cephalosporins | |
CA2935651A1 | Broad spectrum beta-lactamase inhibitors |